Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with Alzheimer’s disease (AD). Recently, we showed that abnormal levels of Aβ42 in cerebrospinal fluid (CSF) can be detected before abnormal amyloid can be detected using PET in individuals with preclinical AD. Using these approaches, here we identify the earliest preclinical AD stage in subjects from the ADNI and BioFINDER cohorts. We show that Aβ accumulation preferentially starts in the precuneus, medial orbitofrontal, and posterior cingulate cortices, i.e., several of the core regions of the default mode network (DMN). This early pattern of Aβ accumulation is already evident in individuals with normal Aβ42 in the CSF and normal amyloid PET who subsequently convert to having abnormal CSF Aβ42. The earliest Aβ accumulation is further associated with hypoconnectivity within the DMN and between the DMN and the frontoparietal network, but not with brain atrophy or glucose hypometabolism. Our results suggest that Aβ fibrils start to accumulate predominantly within certain parts of the DMN in preclinical AD and already then affect brain connectivity.Abnormal levels of Aβ42 in the cerebrospinal fluid occur prior to a positive amyloid PET scan in the brain of individuals with Alzheimer’s disease and here the authors use this temporal pattern to identify individuals with very early stage AD. They show that Aβ fibrils start to accumulate in some of the regions of the default mode network and affect brain connectivity before neurodegeneration occurs.

[1]  Keith A. Johnson,et al.  Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.

[2]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[3]  C. Sorg,et al.  Disrupted Intrinsic Networks Link Amyloid-β Pathology and Impaired Cognition in Prodromal Alzheimer's Disease. , 2015, Cerebral cortex.

[4]  A. Wall,et al.  Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers , 2012, Neurology.

[5]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[6]  C. Sorg,et al.  Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease , 2014, Alzheimer's & Dementia.

[7]  J. Stuart PROCEEDINGS - PART II , 1993 .

[8]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[9]  J. Morris The Clinical Dementia Rating (CDR) , 1993, Neurology.

[10]  Abraham Z. Snyder,et al.  Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion , 2012, NeuroImage.

[11]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[12]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[13]  M. Bondi,et al.  Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors , 2015, Alzheimer's & Dementia.

[14]  Cindee M. Madison,et al.  Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.

[15]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[16]  Keith A. Johnson,et al.  Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.

[17]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[18]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[19]  Thomas T. Liu,et al.  A geometric view of global signal confounds in resting-state functional MRI , 2012, NeuroImage.

[20]  Philip S. Insel,et al.  Emerging β-amyloid pathology and accelerated cortical atrophy. , 2014, JAMA neurology.

[21]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[22]  K. Blennow,et al.  Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET , 2016, Scientific Reports.

[23]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[24]  R. N. Spreng,et al.  The default network and self‐generated thought: component processes, dynamic control, and clinical relevance , 2014, Annals of the New York Academy of Sciences.

[25]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[26]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[27]  C. Jack,et al.  Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid , 2011, Alzheimer's & Dementia.

[28]  Philip S. Insel,et al.  Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. , 2015, JAMA neurology.

[29]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[30]  Marisa O. Hollinshead,et al.  The organization of the human cerebral cortex estimated by intrinsic functional connectivity. , 2011, Journal of neurophysiology.

[31]  Bert Sakmann,et al.  Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease , 2012, Proceedings of the National Academy of Sciences.

[32]  Henrik Zetterberg,et al.  Fluid biomarkers in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[33]  Guojun Bu,et al.  Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.

[34]  Hanna Cho,et al.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.

[35]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[36]  K. Blennow,et al.  Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis , 2013, Multiple sclerosis.

[37]  K. Blennow,et al.  Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. , 2014, JAMA neurology.

[38]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[40]  M. Raichle The brain's default mode network. , 2015, Annual review of neuroscience.

[41]  C. Jack,et al.  Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. , 2015, JAMA neurology.

[42]  K. Blennow,et al.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.

[43]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[45]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[46]  R. Kraftsik,et al.  Primary motor cortex involvement in Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[47]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[48]  D. Salmon,et al.  Subjective Cognitive Complaints Contribute to Misdiagnosis of Mild Cognitive Impairment Nih Public Access , 2022 .

[49]  C. Sorg,et al.  Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease , 2014, Alzheimer's & Dementia.

[50]  R W Cox,et al.  AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. , 1996, Computers and biomedical research, an international journal.

[51]  Thomas T. Liu,et al.  A component based noise correction method (CompCor) for BOLD and perfusion based fMRI , 2007, NeuroImage.

[52]  P. Dupont,et al.  Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease☆ , 2013, NeuroImage: Clinical.

[53]  Cindee M. Madison,et al.  Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability. , 2014, Cerebral cortex.

[54]  Nick C Fox,et al.  Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.

[55]  Mark W. Woolrich,et al.  FSL , 2012, NeuroImage.

[56]  J. Gee,et al.  The Insight ToolKit image registration framework , 2014, Front. Neuroinform..

[57]  B. Hyman,et al.  Neuronal activity and secreted amyloid β lead to altered amyloid β precursor protein and presenilin 1 interactions , 2013, Neurobiology of Disease.

[58]  Karl J. Friston,et al.  Movement‐Related effects in fMRI time‐series , 1996, Magnetic resonance in medicine.

[59]  K. Blennow,et al.  Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis , 2009, Multiple sclerosis.

[60]  G. Antoni,et al.  Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease , 2016, Nature Communications.

[61]  Daniel Rueckert,et al.  Medical Image Computing and Computer-Assisted Intervention − MICCAI 2017: 20th International Conference, Quebec City, QC, Canada, September 11-13, 2017, Proceedings, Part II , 2017, Lecture Notes in Computer Science.

[62]  Frithjof Kruggel,et al.  Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. , 2012, Biochimica et biophysica acta.

[63]  Xiao Han,et al.  Atlas Renormalization for Improved Brain MR Image Segmentation Across Scanner Platforms , 2007, IEEE Transactions on Medical Imaging.

[64]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[65]  Philip S. Insel,et al.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[66]  Edward T. Bullmore,et al.  Network-based statistic: Identifying differences in brain networks , 2010, NeuroImage.

[67]  M. Greicius,et al.  Persistent default‐mode network connectivity during light sedation , 2008, Human brain mapping.

[68]  Keith A. Johnson,et al.  The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials , 2014, Neuron.

[69]  M. Bondi,et al.  Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype. , 2016, Journal of Alzheimer's disease : JAD.

[70]  William J. Jagust,et al.  Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.

[71]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[72]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[73]  Alex Becker,et al.  In vivo characterization of the early states of the amyloid-beta network. , 2013, Brain : a journal of neurology.